Accenture will lead CTD's clinical program in Europe with the goal of gaining regulatory approvals to market orphan drug Trappsol® Cyclo™ for treatment of Niemann-Pick Type C (NPC) disease. NPC ...

ALACHUA, FL--(Marketwired - August 01, 2016) - CTD Holdings, Inc. (CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced its filing ...